We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cornea Preservation Time Study (CPTS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01537393
Recruitment Status : Active, not recruiting
First Posted : February 23, 2012
Last Update Posted : January 4, 2017
National Eye Institute (NEI)
Jaeb Center for Health Research
Information provided by (Responsible Party):
Jonathan Lass, MD, Case Western Reserve University

Brief Summary:
The purpose of this study is to determine if the 3-year graft failure rate following endothelial keratoplasty performed with donor corneas with a preservation time of 8 to 14 days is non-inferior to the failure rate when donor corneas with a preservation time of 7 or fewer days are used.

Condition or disease Intervention/treatment Phase
Cornea Preservation Time Endothelial Keratoplasty Transplant Success Endothelial Cell Density Biological: Cornea tissue transplant Phase 4

Detailed Description:
When the donor cornea is removed from the person who died, it is prepared for transplantation by an eye bank. The donor cornea is placed into a liquid that helps preserve the cornea until it is transplanted. The Food and Drug Administration (FDA) has approved storage of the cornea in this liquid for up to 14 days before the transplant. The purpose of this study is to see if the length of time the donor cornea is kept in the preservation liquid before the transplant affects the likelihood of the transplant being successful. We will follow participants for 3 years after transplant to see if there are any differences in transplant success or in the number of transplanted endothelial cells (the layer of cells that line the undersurface of the cornea) on the corneas that were preserved for 7 days or less compared to those preserved between 8 and 14 days. We have no reason to believe that there is any greater risk for transplant failure with either preservation time group.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of Corneal Preservation Time on Long-Term Graft Success
Study Start Date : March 2012
Estimated Primary Completion Date : March 2017
Estimated Study Completion Date : August 2017

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Preservation Time Group 1
Subjects in this arm will receive cornea tissue preserved for up to 7 days prior to transplant.
Biological: Cornea tissue transplant
Cornea tissue preserved either 7 or less days or 8 to 14 days.
Preservation Time Group 2
Subjects in this arm will receive cornea tissue preserved for 8 to 14 days prior to transplant.
Biological: Cornea tissue transplant
Cornea tissue preserved either 7 or less days or 8 to 14 days.

Primary Outcome Measures :
  1. Corneal Graft Failure [ Time Frame: Participants will be assessed for this outcome for 3 years following surgery ]

    Graft failure, defined as the occurrence of one of the following within 3 years of surgery:

    • Regrafting of the study eye for any reason
    • Cornea which remains cloudy without clearing, according to the following:

      1. cloudy cornea on the first postoperative day which does not clear within 8 weeks OR
      2. cloudy cornea which was initially clear postoperatively but becomes and remains cloudy for 3 months without clearing.

Secondary Outcome Measures :
  1. Endothelial cell density [ Time Frame: 3 years from surgery ]
    Endothelial cell density at 3 years from surgery, conditional on graft survival at 3 years from surgery.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Study Participant Eligibility Criteria

  • Study Participant Inclusion Criteria

    1. Age range 30-<91 years with minimum life expectancy of at least 3 years.
    2. Willingness to return for follow-up study visits at 1 day, 1 week, 1 month, 6 months, 1 year, 2 years and 3 years.
    3. Fluent in English or Spanish.
  • Study Participant Exclusion Criteria 1) Decisionally and/or cognitively impaired

Study Eye Eligibility Criteria

  • Study Eye Inclusion Criteria

    1. EK is scheduled between 10 and 60 days after enrollment

      • The 10-day requirement relates to the need to be able to randomly assign the eye to either intervention group.
      • The 60-day requirement relates to the need to have current eligibility and enrollment data at the time of surgery. If surgery is postponed to >60 days after the initial enrollment visit, a new Baseline Visit and eligibility assessment will have to be performed.
    2. Presence of a condition related to endothelial dysfunction which will be treated by EK.
  • Eligible indications for EK include:

    • Presence of FECD meeting at least one of the following:

      • Phakic FECD
      • Phakic FECD with cataract

        • Triple procedure including EK for FECD, cataract extraction and posterior chamber intraocular lens implantation (IOL) is allowed
      • Aphakic FECD
      • Pseudophakic FECD with posterior capsule supported, suture-fixated, or sulcus-supported posterior chamber IOL
    • Aphakic or pseudophakic corneal edema with posterior capsule supported, suture-fixated, or sulcus-supported posterior chamber IOL without FECD
  • Study Eye Exclusion Criteria

    1. Prior EK
    2. Indication for surgery that is not suitable for EK (e.g, keratoconus, stromal dystrophies and scars)
    3. Presence of a condition that has a very high probability for failure (e.g., failed EK or PKP, heavily vascularized cornea, uncontrolled uveitis)
    4. Other primary endothelial dysfunction conditions including posterior polymorphous corneal dystrophy and congenital hereditary corneal dystrophy
    5. Anterior chamber IOL in study eye prior to or anticipated during EK
    6. Planned intraocular lens exchange of an anterior chamber IOL with a posterior chamber IOL in study eye at time of study EK
    7. Pre-operative central sub-epithelial or stromal scarring that the investigator believes is visually significant and could impact post-operative stromal clarity assessment
    8. Stromal vascularization that is visually significant (by investigator's judgment)
    9. Presence of anterior synechiae (iris to cornea)
    10. Peripheral anterior synechiae (iris to angle) in the angle greater than a total of three clock hours
    11. Hypotony (Intraocular pressure <10 mm Hg)
    12. Uncontrolled (defined as intraocular pressure > 25mm Hg) glaucoma with or without prior filtering surgery or shunt or mini-shunt placement.

      • A shunt or mini-shunt is any device implanted to lower intraocular pressure through an external route (e.g Ahmed) or internal route (e.g. Glaukos) that is present in the anterior chamber angle or extends into the anterior chamber.
    13. Controlled glaucoma with prior shunt or mini-shunt placement for glaucoma

      • Note: FECD or pseudophakic/aphakic corneal edema with posterior chamber IOL that also have undergone filtering surgery (without shunt or mini-shunt) in which glaucoma is currently considered under control will be eligible
    14. Fellow eye visual acuity < 20/200 that is not correctable with EK

Eligibility Criteria for Second Study Eye

  1. Study participant has already enrolled one eye
  2. The second eye meets all study eye inclusion and exclusion criteria (2.2.2 and 2.2.3)
  3. EK surgery in second eye is not planned within 6 weeks of EK on first study eye

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01537393

  Show 40 Study Locations
Sponsors and Collaborators
Case Western Reserve University
National Eye Institute (NEI)
Jaeb Center for Health Research
Study Chair: Jonathan Lass, MD Case Western Reserve University
Principal Investigator: Allison Ayala, MS Jaeb Center for Health Research

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jonathan Lass, MD, Charles I Thomas Professor, Dept. of Ophthalmology & Visual Sciences,, Case Western Reserve University
ClinicalTrials.gov Identifier: NCT01537393     History of Changes
Other Study ID Numbers: CPTS
1U10EY020798-01A1 ( U.S. NIH Grant/Contract )
1U10EY020797-01A1 ( U.S. NIH Grant/Contract )
First Posted: February 23, 2012    Key Record Dates
Last Update Posted: January 4, 2017
Last Verified: January 2017

Keywords provided by Jonathan Lass, MD, Case Western Reserve University:
endothelial keratoplasty

Additional relevant MeSH terms:
Corneal Diseases
Eye Diseases